midazolam has been researched along with Breast Cancer in 15 studies
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Acquired resistance to fulvestrant and palbociclib is a new challenge to treatment of estrogen receptor positive (ER+) breast cancer." | 7.96 | Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib. ( Dubrovskyi, O; Dye, K; Gutgesell, LM; Huang, F; Li, Y; Ratia, K; Shen, Z; Thatcher, GRJ; Tonetti, DA; Xiong, R; Zhao, H; Zhao, J, 2020) |
| "Forty-five breast cancer patients were randomized into three groups: Group I--chemotherapy, control, Group II--midazolam+chemotherapy, and Group III--propofol+chemotherapy." | 6.71 | Effect of sedation with midazolam or propofol on patient's comfort during cancer chemotherapy infusion: a prospective, randomized, double-blind study in breast cancer patients. ( Argun, G; Baran, O; Dikmen Mentes, S; Ertunc, FN; Unsal, D, 2005) |
| " Oral area under the plasma concentration-time curve (AUC) and bioavailability of well known BCRP (sulfasalazine and rosuvastatin), P-glycoprotein (fexofenadine, aliskiren, and talinolol), and CYP3A (midazolam) substrates were investigated in the presence and absence of inhibitors." | 5.48 | Curcumin as an In Vivo Selective Intestinal Breast Cancer Resistance Protein Inhibitor in Cynomolgus Monkeys. ( Abe, K; Ando, O; Imaoka, T; Karibe, T, 2018) |
| " Eighty-two females undergoing breast cancer surgery with propofol-remifentanil anesthesia were enrolled and randomized to receive midazolam 0." | 5.24 | Can quality of recovery be enhanced by premedication with midazolam?: A prospective, randomized, double-blind study in females undergoing breast surgery. ( Kim, MH; Kim, MS; Lee, JH; Lee, JR; Seo, JH, 2017) |
| "The pharmacokinetics of CYC is enantioselective in patients with breast cancer concomitantly treated with epirubicin and ondansetron." | 5.15 | Pharmacokinetics of cyclophosphamide enantiomers in patients with breast cancer. ( Andrade, JM; Coelho, EB; Fernandes, BJ; Lanchote, VL; Matthes, Ado C; Silva, Cde M, 2011) |
| "Acquired resistance to fulvestrant and palbociclib is a new challenge to treatment of estrogen receptor positive (ER+) breast cancer." | 3.96 | Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib. ( Dubrovskyi, O; Dye, K; Gutgesell, LM; Huang, F; Li, Y; Ratia, K; Shen, Z; Thatcher, GRJ; Tonetti, DA; Xiong, R; Zhao, H; Zhao, J, 2020) |
| "To evaluate the relationship of CYP3A activity to breast cancer susceptibility in Chinese Han women using the plasma 1-hydroxymidazolam (1-OHMDZ) to midazolam (MDZ) ratio as the marker of CYP3A activity." | 3.72 | Relationship between CYP3A activity and breast cancer susceptibility in Chinese Han women. ( Chen, XP; Huang, P; Huang, SL; Ouyang, DS; Wang, LS; Zhou, HH; Zhu, B, 2003) |
| "Twenty patients with primary high risk breast cancer were given docetaxel as a 1-h infusion 80 mg/m(2) in a 21-day cycle in 3 cycles followed by 3 cycles of cyclophosphamide, epirubicin and fluorouracil." | 2.76 | NCT01110291: induction of CYP3A activity and lowered exposure to docetaxel in patients with primary breast cancer. ( Hilli, J; Jyrkkiö, S; Laine, K; Pyrhönen, S; Sailas, L, 2011) |
| "Forty-five breast cancer patients were randomized into three groups: Group I--chemotherapy, control, Group II--midazolam+chemotherapy, and Group III--propofol+chemotherapy." | 2.71 | Effect of sedation with midazolam or propofol on patient's comfort during cancer chemotherapy infusion: a prospective, randomized, double-blind study in breast cancer patients. ( Argun, G; Baran, O; Dikmen Mentes, S; Ertunc, FN; Unsal, D, 2005) |
| " Oral area under the plasma concentration-time curve (AUC) and bioavailability of well known BCRP (sulfasalazine and rosuvastatin), P-glycoprotein (fexofenadine, aliskiren, and talinolol), and CYP3A (midazolam) substrates were investigated in the presence and absence of inhibitors." | 1.48 | Curcumin as an In Vivo Selective Intestinal Breast Cancer Resistance Protein Inhibitor in Cynomolgus Monkeys. ( Abe, K; Ando, O; Imaoka, T; Karibe, T, 2018) |
| "Delirium is still one of the most common and distressing symptoms in palliative care patients." | 1.38 | Reversible delirium in an advanced cancer patient. ( Jagsch, C; Kierner, KA; Watzke, HH, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 6 (40.00) | 24.3611 |
| 2020's | 4 (26.67) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Y | 1 |
| Zhao, J | 1 |
| Gutgesell, LM | 1 |
| Shen, Z | 1 |
| Ratia, K | 1 |
| Dye, K | 1 |
| Dubrovskyi, O | 1 |
| Zhao, H | 1 |
| Huang, F | 1 |
| Tonetti, DA | 1 |
| Thatcher, GRJ | 1 |
| Xiong, R | 1 |
| Pleasant, V | 1 |
| Patil, PH | 1 |
| Birangal, S | 1 |
| Shenoy, GG | 1 |
| Rao, M | 1 |
| Kadari, S | 1 |
| Wankhede, A | 1 |
| Rastogi, H | 1 |
| Sharma, T | 1 |
| Pinjari, J | 1 |
| Puralae Channabasavaiah, J | 1 |
| Hong, JM | 1 |
| Han, YH | 1 |
| Lee, D | 1 |
| Hwang, BY | 1 |
| Baik, J | 1 |
| Cho, AR | 1 |
| Lee, HJ | 1 |
| Kim, E | 1 |
| Karibe, T | 1 |
| Imaoka, T | 1 |
| Abe, K | 1 |
| Ando, O | 1 |
| Sato, M | 1 |
| Shirakami, G | 1 |
| Fukuda, K | 1 |
| Kim, MH | 1 |
| Kim, MS | 1 |
| Lee, JH | 1 |
| Seo, JH | 1 |
| Lee, JR | 1 |
| Hilli, J | 1 |
| Sailas, L | 1 |
| Jyrkkiö, S | 1 |
| Pyrhönen, S | 1 |
| Laine, K | 1 |
| Fernandes, BJ | 1 |
| Silva, Cde M | 1 |
| Andrade, JM | 1 |
| Matthes, Ado C | 1 |
| Coelho, EB | 1 |
| Lanchote, VL | 1 |
| Kierner, KA | 1 |
| Jagsch, C | 1 |
| Watzke, HH | 1 |
| Huang, P | 1 |
| Zhu, B | 1 |
| Wang, LS | 1 |
| Ouyang, DS | 1 |
| Huang, SL | 1 |
| Chen, XP | 1 |
| Zhou, HH | 1 |
| Dikmen Mentes, S | 1 |
| Unsal, D | 1 |
| Baran, O | 1 |
| Argun, G | 1 |
| Ertunc, FN | 1 |
| Sessler, DI | 1 |
| Ben-Eliyahu, S | 1 |
| Mascha, EJ | 1 |
| Parat, MO | 1 |
| Buggy, DJ | 1 |
| Ramani, S | 1 |
| Karnad, AB | 1 |
| del Rosario, MA | 1 |
| Martín, AS | 1 |
| Ortega, JJ | 1 |
| Feria, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Magnesium Sulphate Versus Fentanyl as Adjuvants to Propofol Xylocaine Combination for Conscious Sedation During Chronic Subdural Haematoma Surgery. Comparative Study[NCT03548493] | Phase 2 | 34 participants (Actual) | Interventional | 2018-04-10 | Completed | ||
| Activity of CYP3A and Genotypes of CYP3A5 and MDR1 as Predictors of the Clearance and Adverse Effects of Docetaxel, and the Effect of Docetaxel to CYP3A Activity in Previously Untreated Breast Cancer Patients[NCT01110291] | 20 participants (Actual) | Observational | 2003-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for midazolam and Breast Cancer
| Article | Year |
|---|---|
Management of breast complaints and high-risk lesions.
Topics: Breast; Breast Diseases; Breast Neoplasms; Female; Humans; Midazolam; Precancerous Conditions | 2022 |
Long-term subcutaneous infusion of midazolam for refractory delirium in terminal breast cancer.
Topics: Bone Neoplasms; Breast Neoplasms; Delirium; Female; Home Care Services; Humans; Hypnotics and Sedati | 1996 |
6 trials available for midazolam and Breast Cancer
| Article | Year |
|---|---|
Comparison of efficacy between palonosetron-midazolam combination and palonosetron alone for prevention of postoperative nausea and vomiting in patients undergoing breast surgery and patient controlled analgesia: A prospective, randomized, double-blind st
Topics: Analgesia, Patient-Controlled; Anesthetics, Intravenous; Antiemetics; Breast Neoplasms; Double-Blind | 2021 |
Can quality of recovery be enhanced by premedication with midazolam?: A prospective, randomized, double-blind study in females undergoing breast surgery.
Topics: Adult; Aged; Anesthetics, Intravenous; Anxiety; Breast Neoplasms; Double-Blind Method; Emotions; Fem | 2017 |
NCT01110291: induction of CYP3A activity and lowered exposure to docetaxel in patients with primary breast cancer.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Area Under Curve; Breast Neoplasms; Cytochrome P | 2011 |
Pharmacokinetics of cyclophosphamide enantiomers in patients with breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Chemother | 2011 |
Effect of sedation with midazolam or propofol on patient's comfort during cancer chemotherapy infusion: a prospective, randomized, double-blind study in breast cancer patients.
Topics: Adult; Anesthetics, Intravenous; Antineoplastic Agents; Anxiety; Breast Neoplasms; Double-Blind Meth | 2005 |
Can regional analgesia reduce the risk of recurrence after breast cancer? Methodology of a multicenter randomized trial.
Topics: Analgesics, Opioid; Anesthesia, Conduction; Anesthesia, General; Breast Neoplasms; Female; Fentanyl; | 2008 |
7 other studies available for midazolam and Breast Cancer
| Article | Year |
|---|---|
Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib.
Topics: Animals; Breast Neoplasms; Drug Resistance, Neoplasm; Fulvestrant; Humans; MCF-7 Cells; Mice; Models | 2020 |
Molecular dynamics simulation and in vitro evaluation of herb-drug interactions involving dietary polyphenols and CDK inhibitors in breast cancer chemotherapy.
Topics: Breast Neoplasms; Curcumin; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Female; Herb- | 2022 |
Curcumin as an In Vivo Selective Intestinal Breast Cancer Resistance Protein Inhibitor in Cynomolgus Monkeys.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; ATP Binding Cassette Transporter, Subfamily B, Mem | 2018 |
Comparison of general anesthesia and monitored anesthesia care in patients undergoing breast cancer surgery using a combination of ultrasound-guided thoracic paravertebral block and local infiltration anesthesia: a retrospective study.
Topics: Adult; Aged; Amides; Anesthesia Recovery Period; Anesthesia, General; Anesthesia, Local; Breast Neop | 2016 |
Reversible delirium in an advanced cancer patient.
Topics: Amines; Analgesics; Analgesics, Opioid; Bone Neoplasms; Breast Neoplasms; Carcinoma, Intraductal, No | 2012 |
Relationship between CYP3A activity and breast cancer susceptibility in Chinese Han women.
Topics: Aryl Hydrocarbon Hydroxylases; Asian People; Breast Neoplasms; China; Cytochrome P-450 CYP3A; Diseas | 2003 |
Temporary sedation with midazolam for control of severe incident pain.
Topics: Adult; Breast Neoplasms; Female; Humans; Hypnotics and Sedatives; Midazolam; Middle Aged; Osteosarco | 2001 |